Busy Start into 2020: Seven New Projects for Eurice
From youth integration to personalised therapies: Meet our new teams!
While we are just approaching the end of February, this year has already been very exciting and successful for the Eurice team: In January and February 2020, we were lucky to kick off seven brand-new EU research endeavours active in a variety of scientific fields. Kick-off meetings took us to Spain, Greece, Luxembourg or the Netherlands to meet loads of interesting people and dive into the latest developments in the EU research and innovation landscape.
And these are the latest members of the Eurice project family:
cmRNAbone: A Novel Gene Therapy for Bone Regeneration
Launched in January 2020, cmRNAbone has set out to develop a novel bone regenerative therapy for trauma and osteoporosis patients. The researchers plan to develop chemically modified RNAs and a specific vector delivery system to be embedded in a biomaterial formulation tailored to the patients’ needs.
ImmunoSep: Personalised Immunotherapy in Sepsis
Personalised immunotherapy provides hope for reducing mortality in sepsis patients. ImmunoSep, an international collaboration of 14 partners, will explore the usefulness of precision medicine to treat this life-threatening condition while also paving the way for further on-going research in this field. Coordinated by the Radboud University Medical Center, the project will receive just over EUR 10 million funding from the European Union’s Horizon 2020 Framework Programme over the next four years.
SBR: Smart Bone Regeneration
The ten academic and industrial partners collaborating in SBR (Smart Bone Regeneration) aim to improve treatment options for patients with large bone defects. The targeted resorbable bone implant will be based on 3D-printed polymers and include advanced technologies for controlled delivery of active molecules to accelerate bone regeneration. Moreover, the included new sensor technologies will allow post-operative monitoring without regular X-ray examinations.
MIMY: Towards a Better Understanding of Migrant Youth Integration
MIMY has set out to improve the situation of young migrants in Europe through a multi-level analysis of the related integration processes. Collecting qualitative and quantitative data and conducting case studies in various countries, the interdisciplinary consortium will analyse the social and economic effects of (successful or failed) integration in order to derive evidence-based policy recommendations.
HCA Organoid: Establishing an Organoid Cell Atlas
Developing a multi-tissue organoid platform within the “Human Cell Atlas” (HCA) is at the heart of the new EU research project HCA│Organoid. It is one of six pilot actions specifically funded by the European Union’s Horizon 2020 Framework Programme to contribute to this international effort.
PAVE: Understanding the Drivers of Radicalisation and Violent Extremism
PAVE (Preventing and Addressing Violent Extremism through Community Resilience in the Balkans and MENA) aims to tackle the global issue of radicalisation by examining its root causes and driving factors. Based on a comparative assessment of local communities with features of vulnerability or resilience to violent extremism across seven case study countries, the 13 international partner institutions will develop concrete policy proposals to inform citizens and stakeholders within and beyond the regions under study.
ImmUniverse: Transforming Diagnosis and Therapy of Immune-Mediated Diseases
By looking into the common disease mechanisms of Ulcerative Colitis and Atopic Dermatitis, the 26 European partners gathered in ImmUniverse aim at improving diagnostic and therapeutic options for patients living with these conditions. Through molecular profiling techniques, the team will identify signatures of biomarkers and mechanistic principles which reveal information on disease severity and progression enabling personalised therapy decisions for each patient at the right time. With the launch of ImmUniverse, Eurice is now involved in five large-scale research projects funded under the Innovative Medicines Initiative (IMI 2) Joint Undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).